-
公开(公告)号：KR1020110030852A
公开(公告)日：2011-03-24
申请号：KR1020090088480
申请日：2009-09-18
Applicant: 한림제약(주)
IPC: A61K31/675 , A61P19/10 , A61K31/59 , A61K9/20
CPC classification number: A61K9/2077 , A61K9/1623 , A61K9/1652 , A61K9/1694 , A61K9/2027 , A61K31/59 , A61K31/675 , A61K2300/00
Abstract: PURPOSE: A pharmaceutical composition containing bisphosphonate derivative and cholecalciferol for preventing or treating osteoporosis is provided to suppress bone absorption. CONSTITUTION: A pharmaceutical composition for preventing or treating osteoporosis contains risedronic acid or salt thereof, ibandronic acid or salt thereof and 24,000-50,000 IU of cholecalciferol. The composition is administered in tablet form. A pharmaceutical composition for osteoporosis contains: 24,000-50,000 IU of cholecalciferol dissolved in ethanol or ethanol solution; a first stabilizing agent of tocopherol acetate, butylhydroxy toluene, or butylhydroxyanisole; cholecalciferol-containing granules; 5-20 weight% of mannitol as a second stabilizing agent; and risedronic acid or salt thereof, ibandronic acid or salt thereof.
Abstract translation: 目的：提供含有双膦酸衍生物和胆钙化醇用于预防或治疗骨质疏松症的药物组合物，以抑制骨吸收。 构成：用于预防或治疗骨质疏松症的药物组合物含有利塞膦酸或其盐，伊班膦酸或其盐和24,000-50,000IU的胆钙化甾醇。 组合物以片剂形式施用。 用于骨质疏松症的药物组合物包含：溶解在乙醇或乙醇溶液中的24,000-50,000IU的胆钙化甾醇; 乙酸生育酚，丁基羟基甲苯或丁基羟基苯甲醚的第一稳定剂; 含胆钙化醇的颗粒; 5-20重量％的甘露醇作为第二稳定剂; 和利塞膦酸或其盐，伊班膦酸或其盐。
-
公开(公告)号：KR1020100060673A
公开(公告)日：2010-06-07
申请号：KR1020080119366
申请日：2008-11-28
Applicant: 한림제약(주)
CPC classification number: A61K36/87 , A61K9/0048
Abstract: PURPOSE: A pharmaceutical composition of eye drop liquids and solutions or gels containing Vitis vinifera seed extract and antioxidant is provided to maintain physical and chemical stability. CONSTITUTION: A pharmaceutical composition of eye drop liquids and solutions or gels contains 0.1-30 weight% of Vitis vinifera seed extract, ascorbic acid or salt thereof, sodium bisulfate, potassium metabisulphite, or L-threonine, or antioxidant of salt thereof. The Vitis vinifera seed extract contains 80-130 of procyanidolic value(PCV); 30% or less (+)catechin and (-) epicatechin; and 95-105% of proanthocyanidine.
Abstract translation: 目的：提供含有葡萄种子提取物和抗氧化剂的滴眼液和溶液或凝胶的药物组合物，以维持物理和化学稳定性。 构成：滴眼液和溶液或凝胶的药物组合物含有0.1-30重量％的葡萄籽种子提取物，抗坏血酸或其盐，硫酸氢钠，偏亚硫酸氢钾或L-苏氨酸或其盐的抗氧化剂。 葡萄籽提取物含有原花青素含量（PCV）80-130; 30％以下（+）儿茶素和（ - ）表儿茶素; 和95-105％的原花青素。
-
公开(公告)号：KR1020120112162A
公开(公告)日：2012-10-11
申请号：KR1020120032161
申请日：2012-03-29
Applicant: 한국화학연구원 , 가톨릭대학교 산학협력단
IPC: A61K31/4164 , A61K31/35 , A61P27/02
CPC classification number: A61K9/0048 , A61K31/4178
Abstract: PURPOSE: A pharmaceutical composition containing secondary amine-substituted benzopyrane derivative is provided to prevent or treat macular degeneration. CONSTITUTION: A pharmaceutical composition for preventing or treating macular degeneration contains a compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. The composition is used in the form of eye drops and the active ingredients are delivery to retina. Eye drops for preventing or treating macular degeneration contain the compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. A pharmaceutical composition for preventing or treating macular degeneration contains (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazole-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyrane or pharmaceutically acceptable salt thereof as an active ingredient.
Abstract translation: 目的：提供含有仲胺取代苯并吡喃衍生物的药物组合物，用于预防或治疗黄斑变性。 构成：用于预防或治疗黄斑变性的药物组合物含有化学式1的化合物或其药学上可接受的盐作为活性成分。 组合物以眼药水的形式使用，活性成分被输送到视网膜。 用于预防或治疗黄斑变性的眼药水含有化学式1的化合物或其药学上可接受的盐作为活性成分。 用于预防或治疗黄斑变性的药物组合物含有（2R，3R，4S）-6-氨基-4- [N-（4-氯苯基）-N-（1H-咪唑-2-基甲基）氨基] -3-羟基 -2-甲基-2-二甲氧基甲基-3,4-二氢-2H-1-苯并吡喃或其药学上可接受的盐作为活性成分。
-
公开(公告)号：KR101099021B1
公开(公告)日：2011-12-28
申请号：KR1020090035796
申请日：2009-04-24
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: 본 발명은 유럽종 포도(
Vitis vinifera )의 씨 추출물 및 약학적으로 허용가능한 담체를 포함하는 골관절염(osteoarthritis)의 예방 또는 치료용 약학 조성물을 제공한다.
유럽종 포도의 씨 추출물, 골관절염-
公开(公告)号：KR101096574B1
公开(公告)日：2011-12-20
申请号：KR1020080126216
申请日：2008-12-12
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: 본 발명은 유럽종 포도(
Vitis vinifera )의 씨 추출물 및 약제학적으로 허용가능한 담체를 포함하는 골다공증의 예방 또는 치료용 약학 조성물을 제공한다.
유럽종 포도, 골다공증-
Patent Agency Ranking26.发明公开
公开(公告)号：KR1020100067708A
公开(公告)日：2010-06-22
申请号：KR1020080126216
申请日：2008-12-12
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract is provided to suppress osteoclast differentiation and to prevent and treat osteoporosis. CONSTITUTION: A pharmaceutical composition for preventing or treating osteoporosis contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The Vitis vinifera seed extract has 80-130 of procyanidolic value(PCV), 30% or less (+) catechin and (-) epicatechin, and 95-105% of proanthocyanine. A method for manufacturing the Vitis vinifera seed extract comprises: a step of adding mixture solvent of water and acetone to pulverized Vitis vinifera seed and extracting at room temperature; a step of removing acetone and suturing sodium chloride and filtering; a step of extracting the extract with acetate and concentrating; and a step of adding chloroform to the concentrate and filtering.
Abstract translation: 目的：提供含有葡萄籽提取物的药物组合物，以抑制破骨细胞分化和预防和治疗骨质疏松症。 构成：用于预防或治疗骨质疏松症的药物组合物含有葡萄种子提取物和药学上可接受的载体。 葡萄籽提取物的原花青素值（PCV）为80-130，儿茶素和（ - ）表儿茶素为30％以下，原花青素为95-105％。 葡萄种子提取物的制造方法包括：将水和丙酮的混合溶剂加入粉状葡萄种子并在室温下提取的步骤; 去除丙酮并缝合氯化钠并过滤的步骤; 用醋酸提取提取物浓缩的步骤; 以及向浓缩物中加入氯仿并过滤的步骤。
-
公开(公告)号：KR101187195B1
公开(公告)日：2012-10-02
申请号：KR1020100025050
申请日：2010-03-22
Applicant: 에이치 엘 지노믹스(주) , 가톨릭대학교 산학협력단
Abstract: 본 발명은 유럽종 포도(
Vitis vinifera )의 씨 추출물 및 약학적으로 허용가능한 담체를 포함하는 위장관 궤양(gastrointestinal ulcer)의 예방 또는 치료용 약학 조성물을 제공한다.-
公开(公告)号：KR1020110137588A
公开(公告)日：2011-12-23
申请号：KR1020100057601
申请日：2010-06-17
Applicant: 에이치 엘 지노믹스(주) , 가톨릭대학교 산학협력단
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract and pharmaceutically acceptable carrier is provided to prevent and treat obesity. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The extract has 80-130 of procyanidolic value(PCV) and contains less than 30% of (+)catechin and (-) epicatechin and 95-105% of proanthocyanidin content. A method for preparing the extract comprises: a step of mixing pulverized Vitis vinifera seed and a mixture solvent of acetone and water and isolating at room temperature; a step of filtering the extract and distilling the filtered liquid to remove acetone; a step of saturating sodium chloride and filtering; a step of extracting the liquid with ethyl acetate and concentrating; and a step of adding chloroform and filtering.
Abstract translation: 目的：提供含有葡萄籽提取物和药学上可接受的载体的药物组合物以预防和治疗肥胖症。 构成：用于预防或治疗肥胖症的药物组合物含有葡萄种子提取物和药学上可接受的载体。 提取物具有80-130原花青素值（PCV），并且含有少于30％的（+）儿茶素和（ - ）表儿茶素和95-105％的原花色素含量。 一种制备提取物的方法包括：将经粉碎的葡萄种子和丙酮和水的混合溶剂混合并在室温下分离的步骤; 过滤提取物并蒸馏过滤的液体以除去丙酮的步骤; 使氯化钠饱和并过滤的步骤; 用乙酸乙酯萃取液体并浓缩的步骤; 并加入氯仿和过滤步骤。
-
公开(公告)号：KR1020110049627A
公开(公告)日：2011-05-12
申请号：KR1020100025050
申请日：2010-03-22
Applicant: 에이치 엘 지노믹스(주) , 가톨릭대학교 산학협력단
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract is provided to prevent and treat gastrointestinal ulcer. CONSTITUTION: A pharmaceutical composition for preventing or treating gastrointestinal ulcer contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The extract of Vitis vinifera seeds contains 80-130 of procyanidolic value(PCV); 30% or less of (+)catechin and (-) epicatechin; and 95-105% of proanthocyanidin. A method for preparing the Vitis vinifera seed extract comprises: a step of extracting Vitis vinifera seed seeds in a mixture solvent of acetone and water and filtering; a step of distilling liquid and removing acetone; a step of saturating sodium chloride and filtering; a step of extracting the liquid with ethyl acetate and concentrating; and a step of adding chloroform and filtering to obtain precipitate.
Abstract translation: 目的：提供含有葡萄籽提取物的药物组合物，用于预防和治疗胃肠溃疡。 构成：用于预防或治疗胃肠溃疡的药物组合物含有葡萄种子提取物和药学上可接受的载体。 葡萄籽提取物含有原花青素含量（PCV）80-130; 30％以下（+）儿茶素和（ - ）表儿茶素; 和95-105％的原花色素。 一种葡萄种子提取物的制备方法，其特征在于：在丙酮和水的混合溶剂中提取葡萄种子种子并过滤; 蒸馏液并除去丙酮的步骤; 使氯化钠饱和并过滤的步骤; 用乙酸乙酯萃取液体并浓缩的步骤; 并加入氯仿和过滤以获得沉淀物的步骤。
-
公开(公告)号：KR1020100117184A
公开(公告)日：2010-11-03
申请号：KR1020090035796
申请日：2009-04-24
Applicant: 가톨릭대학교 산학협력단 , 에이치 엘 지노믹스(주)
CPC classification number: A61K36/87
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera for preventing or treating osteoarthritis is provided. CONSTITUTION: A pharmaceutical composition for preventing or treating osteoarthritis contains Vitis vinifera extract and pharmaceutically acceptable carrier. Osteoarthritis is caused by aging, obesity or trauma. The Vitis vinifera extract contains 80-130 of procyanidolic value(PCV), 30% or less (+) catechin and (-) epicatechin, and 95-105% of proanthocyanidine. A method for producing Vitis vinifera extract comprises: a step of extracting Vitis vinifera and mixture of acetone and water at room temperature and filtering; a step of distilling remaining liquid and removing acetone; a step of saturating sodium chloride and filtering; a step of extracting with ethyl acetate and concentrating; and a step of adding chloroform and precipitating.
Abstract translation: 目的：提供一种含有葡萄酒的预防或治疗骨关节炎的药物组合物。 构成：用于预防或治疗骨关节炎的药物组合物含有葡萄葡萄提取物和药学上可接受的载体。 骨关节炎是由衰老，肥胖或创伤引起的。 葡萄籽提取物含有原花青素值（PCV）80-130，儿茶素和（ - ）表儿茶素30％以下，原花青素95-105％。 一种葡萄酒提取物的制备方法，其特征在于：在室温下提取葡萄酒和丙酮与水的混合物，过滤; 蒸馏剩余液体并除去丙酮的步骤; 使氯化钠饱和并过滤的步骤; 用乙酸乙酯提取并浓缩的步骤; 并加入氯仿和沉淀的步骤。
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.028 seconds)
